Join this live webinar to learn more.
Molecular residual disease (MRD) is rapidly gaining traction as a critical biomarker in oncology, offering earlier and more sensitive detection of disease persistence and recurrence. By offering real-time insights into tumor dynamics, MRD is transforming clinical trial design. As regulatory bodies increasingly recognize MRD as a surrogate trial endpoint, its integration into clinical development strategies has become essential for pharma and biotech organizations aiming to accelerate and de-risk oncology pipelines.
Join our expert panel as we examine the strategic use of MRD tests in solid tumor clinical trials. We will also introduce RaDaR ST, the latest solution from NeoGenomics for tumor-informed MRD, and review key analytical performance data and clinical trial results.
Key Topics Include:
- Leveraging MRD as a tool to optimize clinical trial design
- Introduction to RaDaR ST, featuring key analytical performance highlights
- Case studies from clinical trial partnerships illustrating the real-world impact of MRD utilization in oncology pipelines.
Offered Free by: NeoGenomics Laboratories
See All Resources from: NeoGenomics Laboratories
